Pancreatic Cancer Vaccine Triggers Strong T-Cell Response in Nearly All Patients but Fails to Delay Relapse

Promising Immune Activation Falls Short: New US Pancreatic Cancer Vaccine Misses Key Goal

According to НВ — Техно: Elicio Therapeutics has revealed findings from the Phase 2 trial of their experimental onco-vaccine, camupepimut (ELI-002 7P), designed to target pancreatic tumors driven by KRAS gene mutations. While the vaccine successfully sparked a robust T-cell immune response in 99% of evaluable patients, it did not significantly postpone disease recurrence. The study involved 144 patients and was presented at the European Society for Medical Oncology congress in Madrid.

Key Study Insights

Camupepimut was administered to 96 patients with KRAS-mutated pancreatic cancer, with 48 patients monitored as a control group. Despite strong immunogenicity, the vaccine did not meet its primary endpoint of extending the time before cancer relapse across the entire cohort. However, among patients who initially had no detectable circulating tumor DNA, those treated with the vaccine experienced fewer recurrences.

The distribution of patients may have influenced outcomes, as the vaccinated group included a greater proportion of high-risk individuals. Elicio Therapeutics is considering launching a larger Phase 3 trial to further evaluate the vaccine’s potential. Currently, camupepimut remains experimental and is not approved for routine clinical use.

The trial results were published in the prestigious journal Nature Medicine, highlighting their relevance for ongoing pancreatic cancer research. This update was released on November 2 at 16:46.

Although camupepimut demonstrates encouraging capacity to stimulate immune defenses, the lack of a significant delay in cancer recurrence underscores the need for continued investigation. Future studies will incorporate patient risk profiles to refine treatment strategies, which is critical given the complex and aggressive nature of pancreatic cancer. These findings emphasize the importance of sustained research efforts in this challenging field of oncology.

While the promising results of the camupepimut vaccine highlight its potential in activating immune responses against pancreatic cancer, recent advancements in personalized medicine have shown significant progress in other cancer types. For instance, a personalized mRNA vaccine has demonstrated a 42% reduction in melanoma recurrence during a Phase 3 trial, underscoring the evolving landscape of cancer immunotherapy. Exploring such developments can provide valuable insights into effective treatment strategies.